ArticleHaematologica2018
Iron overload impairs normal hematopoietic stem and progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice.
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 70 citations in OpenAlex.
- Iron chelation of hetrombopag in aplastic anemia: a post hoc analysis of a phase II study.Annals of hematology · 2022Trial
- Therapeutic Silencing of Tmprss6 Reduces Iron-Induced Inflammation and Prolongs Survival in MDS Mice.American journal of hematology · 2026Article
- Article
- Ferrostatin-1 and hinokitiol supplementation enhance human hematopoietic stem cell expansion in a chemically defined medium.Molecular therapy. Advances · 2026Article
- Impact of iron overload on hematopoietic stem cell transplantation in pediatric patients with nonmalignant hematological disorders.Blood advances · 2026Observational
- Potential diagnostic, prognostic, and therapeutic implications of ferroptosis in myelodysplastic syndromes.Discover oncology · 2026Review
- Longitudinal clinical and preclinical studies identify hetrombopag as a potent chelator for systemic iron overload.HemaSphere · 2026Article
- Platelet-mediated progression of fatty liver disease in metabolic dysfunction-associated steatohepatitis: a pathophysiological review.Frontiers in medicine · 2026Review
- Iron chelation therapy in myelodysplastic syndromes and allogeneic hematopoietic cell transplantation, a delicate balance.Blood reviews · 2025Review
- Fe-doped MOF nanoparticles: the LIFR and BMP4 dual-signaling pathways activated regulator for in vitro expansion of mouse embryonic stem cells.Materials today. Bio · 2025Article
- Clinical features and outcomes of myelodysplastic syndrome patients with iron overload: a single-center retrospective study.European journal of medical research · 2025Article
- Deferasirox improved iron homeostasis and hematopoiesis in ovariectomized rats with iron accumulation.Scientific reports · 2025Article
- The role of mitochondria in iron overload-induced damage.Journal of translational medicine · 2024Review
- Competition of dualBlood neoplasia · 2024Article
- Ironing out the role of ferroptosis in immunity.Immunity · 2024Review
- Role of reactive oxygen species in myelodysplastic syndromes.Cellular & molecular biology letters · 2024Review
- Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts.Cancer research · 2024Article
- Increased iron uptake by splenic hematopoietic stem cells promotes TET2-dependent erythroid regeneration.Nature communications · 2024Article
- Rapid and Live-Cell Detection of Senescence in Mesenchymal Stem Cells by Micro Magnetic Resonance Relaxometry.Stem cells translational medicine · 2023Article
- Recent Advancements in Poor Graft Function Following Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is increasing clinical evidence to suggest a suppressive effect on hematopoiesis in myelodysplastic syndrome patients with iron overload. However, how iron overload influences hematopoiesis in myelodysplastic syndrome (MDS) remains unknown. Here, the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.